Watchlist Price Alert

Regeneron Pharmaceuticals... (REGN)

NASDAQ: REGN · Real-Time Price · USD

604.66

14.66 (2.48%)

At close: May 02, 2025, 3:59 PM

605.61

0.16%

After-hours: May 02, 2025, 05:37 PM EDT

2.48% (1D)

Bid	600
Market Cap	64.67B
Revenue (ttm)	14.09B
Net Income (ttm)	4.5B
EPS (ttm)	39.34
PE Ratio (ttm)	15.37
Forward PE	12.72
Analyst	Buy

Ask	611.9
Volume	1,270,298
Avg. Volume (20D)	1,058,920
Open	598.00
Previous Close	590.00
Day's Range	598.00 - 614.88
52-Week Range	525.99 - 1211.20
Beta	0.43

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlus...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 2, 1991

Employees 15,158

Stock Exchange NASDAQ

Ticker Symbol REGN

Website https://www.regeneron.com

Full Company Profile

Analyst Forecast

According to 23 analyst ratings, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $940, which is an increase of 55.46% from the latest price.

Stock Forecasts

Earnings Surprise

Regeneron Pharmaceuticals has released their quartely earnings on Apr 29, 2025:

Revenue of $3.03B misses estimates by $261M, with -3.69% YoY decline.

EPS of 8.22 misses estimates by -0.60, with -13.93% YoY decline.

Why Price Moved

4 days ago

+5.25%

Regeneron shares are trading higher after falling ... Unlock content with Pro Subscription

5 days ago

-6.87%

Regeneron Pharmaceuticals shares are trading lower after the company reported wore-than-expected Q1 financial results.

News

5 days ago · benzinga.com

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82.

5 days ago · zacks.com

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.

5 days ago · seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, Pres...

5 days ago · investopedia.com

Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More

U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and t...

4 days ago · zacks.com

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima...

5 days ago · barrons.com

Regeneron Stock Plummets After Earnings Miss

First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet.

5 days ago · zacks.com

Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates

Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago.

5 days ago · reuters.com

Regeneron Pharma's first-quarter results miss on lower Eylea demand

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket tra...

5 days ago · youtube.com

BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results

Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.

6 days ago · zacks.com

Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.

Load More News